CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent. The company reported quarterly sales of $3.38 million which missed the analyst consensus estimate of $5.47 million by 38.08 percent. This is a 11.55 percent decrease over sales of $3.83 million the same period last year.
CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated